Indaptus Therapeutics (INDP) Non Operating Income (2020 - 2025)
Indaptus Therapeutics (INDP) posted quarterly Non Operating Income of $40129.0 for Q1 2025, down 70.61% year-over-year from $136562.0 in Q1 2024, and down 0.97% quarter-over-quarter from $40523.0 in Q4 2024.
Indaptus Therapeutics (INDP) Non Operating Income (2020 - 2025) Analysis & Trends
Indaptus Therapeutics' Non Operating Income history runs 6 years deep, the most recent figure standing at $40129.0 for Q1 2025.
- In Q1 2025, Non Operating Income fell 70.61% year-over-year to $40129.0; the TTM figure through Mar 2025 stood at $247291.0 (down 72.2% YoY), while the FY2024 annual figure was $343724.0, down 64.01% from the prior year.
- Non Operating Income for Q1 2025 stood at $40129.0, down from $40523.0 in the prior quarter.
- The five-year high for Non Operating Income was $431246.0 in Q4 2022, with the low at $827.0 in Q3 2021.
- The 5-year median for Non Operating Income is $73021.0 (2024), against an average of $114393.2.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income soared 19736.52% in 2022, then sank 77.6% in 2024.
- Indaptus Therapeutics' Non Operating Income stood at $2174.0 in 2021, then jumped by 19736.52% to $431246.0 in 2022, then sank by 58.99% to $176854.0 in 2023, then sank by 77.09% to $40523.0 in 2024, then declined by 0.97% to $40129.0 in 2025.
- Business Quant data shows INDP's Non Operating Income at $40129.0 in Q1 2025, $40523.0 in Q4 2024, and $73021.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 40,129.00 |
| Dec 31, 2024 | 40,523.00 |
| Sep 30, 2024 | 73,021.00 |
| Jun 30, 2024 | 93,618.00 |
| Mar 31, 2024 | 136,562.00 |
| Dec 31, 2023 | 176,854.00 |
| Sep 30, 2023 | 326,024.00 |
| Jun 30, 2023 | 250,197.00 |
| Mar 31, 2023 | 201,928.00 |
| Dec 31, 2022 | 431,246.00 |
| Sep 30, 2022 | 86,184.00 |
| Jun 30, 2022 | 33,758.00 |
| Mar 31, 2022 | 36,919.00 |
| Dec 31, 2021 | 2,174.00 |
| Sep 30, 2021 | 827.00 |
| Jun 30, 2021 | 13,166.00 |
| Mar 31, 2021 | 1,554.00 |
| Dec 31, 2020 | -1,667.00 |
| Sep 30, 2020 | 3,680.00 |
| Jun 30, 2020 | 4,000.00 |